Sign inJoin waitlistJoin the waitlist

Catherine Diefenbach

Director, Hematology Translational Research, Perlmutter Cancer Center · NYU Grossman School of Medicine

Credentials: · · · ·

History

Hematology Translational Research · NYU Grossman School of Medicine
Present
Clinical Lymphoma Program · NYU Grossman School of Medicine
Present
NYU Grossman School of Medicine · NYU Grossman Long Island School of Medicine
Present

Hematology and Medical Oncology
Memorial Sloan Kettering Cancer Center
2005–2008
Internal Medicine
Johns Hopkins Hospital
2001–2004
Perelman School of Medicine at the University of Pennsylvania
1997–2001

Research

The bone marrow microenvironment at single-cell resolution
Nature · 2019 · 750 citations
Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study
Journal of Clinical Oncology · 2022 · 285 citations
Phase I trial of overlapping long peptides from a tumor self-antigen and poly-ICLC shows rapid induction of integrated immune response in ovarian cancer patients
Clinical Cancer Research · 2012 · 227 citations

Ranjana Advani
16 papers
BK
Brad Kahl
12 papers
Reem Karmali
12 papers
Nancy Bartlett
11 papers
Yun Choi
11 papers · 8 as a fellow
Andrew Evens
10 papers
KD
Kevin David
10 papers
Veronika Bachanova
9 papers
Deepa Jagadeesh
8 papers · 1 as a fellow
Gaurav Varma
8 papers · 8 as a resident
Izidore Lossos
8 papers
Julio Chavez
8 papers

Grants

LTBR CARs as Next-Generation Therapies for R/R Lymphoma
National Cancer Institute · R01
PI · $3.2M · New York Genome Center
2023–2028
A Prospective Evaluation of the Gut Microbiome as a Mediator of Lymphoma Treatment Outcome and Systemic Immunity
National Cancer Institute · R01
Contact PI · $3.5M · New York University School of Medicine
2022–2027
Cancer Center Support Grant
National Cancer Institute · P30
Project lead · $54.2K · New York University School of Medicine
1997–2024
A Novel Multimodality Immune Based Platform in Advanced Mycosis Fungoides
National Cancer Institute · R03
Contact PI · $169.5K · New York University School of Medicine
2014–2017

Clinical trials

Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma
Principal investigator · Recruiting · Phase 1
National Cancer Institute (NCI)
2022–2027
Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
Principal investigator · Terminated · Phase 2
Academic and Community Cancer Research United
2021–2024
Safety & Efficacy Study of Combination of Pembrolizumab and Lenalidomide, in Patients With Relapsed Non-Hodgkin and Hodgkin Lymphoma
Principal investigator · Terminated · Phase 1, Phase 2
NYU Langone Health
2016–2017
Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
Principal investigator · Active not recruiting · Phase 1, Phase 2
National Cancer Institute (NCI)
2014–2026